Mark T. Dunbar, OD, FAAO, and David Eichenbaum, MD, FASRS, break down the role of presbyopia-correcting drops and how they fill an unmet need for patients who want to be spectacle-free but may not be ready for surgical options. Drs. Dunbar and Eichenbaum also explain how not all miotics behave in the same way.
The Role of Presbyopia-Correcting Drops
Media formats available:
Details
Presenters
Target Audience
This certified continuing medical education activity is designed for ophthalmologists and optometrists who treat patients with posterior segment disease.
Grantor Statement
This activity is supported by an unrestricted educational grant Orasis Pharmaceuticals.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Explain how presbyopia-correcting drops improve near visual acuity and affect functional vision
- Review clinical trial and real-world safety data for presbyopia-correcting drops, with a focus on the risk of vitreoretinal complications
- Describe clinical tests that may be useful to examine patients considering presbyopia-correcting drops
- Assess patient candidacy for presbyopia-correcting drops based on ocular anatomy, ocular history, and lifestyle
- Collaborate with optometry colleagues to devise follow-up regimens and provide patient education for those being treated with presbyopia-correcting drops
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this an eduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Evolve Medical Education LLC is a COPE-accredited administrator.
Sponsored by
This activity, COPE Activity Number 130978, is accredited by COPE for continuing education for optometrists. This course is approved for 0.25 hour of CE.
Course #: 98361-PH
Activity #: 130978COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Faculty
Mark T. Dunbar, OD, FAAO
Director of Optometry
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL
David Eichenbaum, MD
Director of Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor
Morsani College of Medicine
University of South Florida
Tampa, FLDisclosure of Relevant Financial Relationships
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
Mark T. Dunbar, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Avellino, Azura, Bausch + Lomb, Carl Zeiss Meditec, Cloudbreak, Glaukos, Orasis Pharmaceuticals, Reed Exhibitions, Tarsus Pharma, Iveric/Astellas, Sight Sciences, Sun Pharma, Sydnexis, Thea Pharmaceuticals, Topcon, TruKera, and Visus. Advisory Board: Carl Zeiss Meditec, Reed Exhibitions, and Tarsus Pharma. Speaker’s Bureau: Carl Zeiss Meditec.
David Eichenbaum, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4D Molecular Therapeutics, AbbVie, Alimera Sciences, Annexon, Apellis Pharmaceuticals, Bausch & Lomb, Bayer, Boehringer Ingelheim, Coherus, Complement Therapeutics, CorEvitas/Vestrum, Crinetics, EcoR2, EyePoint Pharmaceuticals, Genentech, Harrow, Kodiak Sciences, Kriya, Neurotech, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Ollin, Opthea, Outlook, RecensMedical, Regeneron, RegenxBio, ReVive, RetinAI, Roche, Samsara, Stealth, Tilak, and Unity. Grant/Research Support: 4D Molecular Therapeutics, Aerie/Alcon, Alexion, Allegenesis, Annexon, Aviceda, Bayer, EyeBio, EyePoint I Pharmaceuticals, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak Sciences, Kyowa Kirin, Mylan, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, Priovant, RecensMedical, Regeneron, RegenxBio, RetinAI, Roche, Stealth, and Unity. Advisory Board: Amaros and Ollin. Common Stock: 4D Molecular Therapeutics, Amaros, EyePoint Pharmaceuticals, Janssen, and ReVive. Speaker’s Bureau: Apellis Pharmaceuticals, Bayer, Genentech, and Regeneron.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Orasis Pharmaceuticals.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Christina Y. Weng, MD, MBA, FASRS
Mohammad R. Rafieetary, OD, FAAO, FORS, ABO
- CME/CE Broadcast Replay
Eye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
1.00 creditKathleen N. Moore, MD, MS, FASCO
Aaron Samuel Gold, OD, FAAO
Carlo J. Pelino, OD, FAAO
Kathleen N. Moore, MD, MS, FASCO
Kamran M. Riaz, MD
Aaron Samuel Gold, OD, FAAO
Carlo J. Pelino, OD, FAAO
